Arcus Biosciences stock advances casdatifan toward Phase 3 milestones
Published on 11/13/2026 at 00:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSArcus sharpens kidney cancer strategy
- Arcus expects to complete enrollment in the PEAK-1 Phase 3 study within two to three months.
- The company plans to start the PEAK-20 Phase 3 study by year-end 2026.
- Cash, cash equivalents and marketable securities totaled 694 million US dollars at September 30, 2026, with funding expected into 2029 after an October equity financing.
Arcus Biosciences is moving its casdatifan program toward pivotal kidney cancer studies after reporting third-quarter results on November 4, 2026. In its company release, management said enrollment in PEAK-1, a Phase 3 study of casdatifan plus cabozantinib in second-line clear cell renal cell carcinoma, should finish within two to three months.
Clinical milestones move closer
Arcus also expects to begin PEAK-20 by the end of 2026. The first-line Phase 3 trial will evaluate casdatifan with ipilimumab and nivolumab. Additional ARC-20 readouts, including more mature progression-free survival and overall survival data, are expected in 2027.
The October ARC-20 update included a 50 percent confirmed objective response rate for casdatifan plus zimberelimab in a first-line cohort of 30 patients. In second-line disease, the casdatifan and cabozantinib combination showed median progression-free survival of 14.5 months in a 43-patient cohort, while median overall survival had not been reached at the data cutoff of September 4, 2026. These results are cross-trial comparisons rather than head-to-head evidence, and the company says investigational molecules have not received regulatory approval.
Revenue falls as collaborations wind down
Third-quarter revenue was 9 million US dollars, down from 26 million US dollars a year earlier, primarily because activities under the Gilead collaboration were winding down or reaching completion. Research and development expenses fell to 117 million US dollars from 141 million US dollars, while the net loss narrowed to 128 million US dollars from 135 million US dollars.
Arcus expects full-year 2026 GAAP revenue of 70 million to 75 million US dollars. Cash, cash equivalents and marketable securities stood at 694 million US dollars at September 30, 2026; management said that balance together with 288 million US dollars in gross proceeds from an October equity financing should fund planned operations into 2029.
Arcus focuses on specialist oncology
Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California. It develops small-molecule medicines, antibodies and combination therapies for cancer and immune diseases, with casdatifan in kidney cancer and quemliclustat in pancreatic cancer as its leading Phase 3 oncology programs. In kidney cancer, its specialist development model targets treatment settings shaped by Merck's pembrolizumab, Bristol Myers Squibb's ipilimumab and nivolumab, and Exelixis's cabozantinib, while Arcus seeks to establish casdatifan across multiple lines of care.
Arcus Biosciences at a glance
- Company: Arcus Biosciences, Inc.
- Ticker: RCUS
- Exchange: New York Stock Exchange
- Third-quarter revenue: 9 million US dollars for the period ended September 30, 2026
- Third-quarter net loss: 128 million US dollars
- Cash and marketable securities: 694 million US dollars at September 30, 2026
Investors will focus on the timing of PEAK-1 enrollment, the start of PEAK-20 and the durability of casdatifan data as Arcus shifts resources toward its lead oncology program.
The wider biotech market remains sensitive to clinical milestones and financing conditions; follow the S&P 500 for the broader market setting.
